PolyPid to Participate in The Citizens Life Sciences Conference
PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced its participation in The Citizens Life Sciences Conference in New York. The company's management will engage in a fireside chat on Wednesday, May 7, 2025, at 10:30 AM ET.
During the two-day conference, scheduled for May 7-8, 2025, the PolyPid management team will also be available for one-on-one investor meetings. Interested investors can arrange meetings through their Citizens JMP representatives.
PolyPid (Nasdaq: PYPD), un'azienda biofarmaceutica in fase avanzata focalizzata sul miglioramento degli esiti chirurgici, ha annunciato la sua partecipazione alla Citizens Life Sciences Conference a New York. Il management dell'azienda parteciperà a una conversazione informale il mercoledì 7 maggio 2025, alle 10:30 ET.
Durante la conferenza di due giorni, prevista dal 7 all'8 maggio 2025, il team di gestione di PolyPid sarà inoltre disponibile per incontri individuali con gli investitori. Gli investitori interessati possono organizzare gli incontri tramite i loro rappresentanti Citizens JMP.
PolyPid (Nasdaq: PYPD), una empresa biofarmacéutica en etapa avanzada centrada en mejorar los resultados quirúrgicos, ha anunciado su participación en la Citizens Life Sciences Conference en Nueva York. La dirección de la compañía participará en una charla informal el miércoles 7 de mayo de 2025, a las 10:30 AM ET.
Durante la conferencia de dos días, programada del 7 al 8 de mayo de 2025, el equipo directivo de PolyPid también estará disponible para reuniones individuales con inversores. Los inversores interesados pueden coordinar reuniones a través de sus representantes de Citizens JMP.
PolyPid (나스닥: PYPD)는 수술 결과 개선에 중점을 둔 후기 단계 바이오제약 회사로, 뉴욕에서 열리는 Citizens Life Sciences Conference에 참여한다고 발표했습니다. 회사 경영진은 2025년 5월 7일 수요일 오전 10시 30분(동부시간)에 진행되는 대담에 참여할 예정입니다.
2025년 5월 7일부터 8일까지 이틀간 열리는 이번 컨퍼런스 동안 PolyPid 경영진은 1:1 투자자 미팅도 진행할 예정입니다. 관심 있는 투자자는 Citizens JMP 담당자를 통해 미팅을 예약할 수 있습니다.
PolyPid (Nasdaq : PYPD), une société biopharmaceutique en phase avancée axée sur l'amélioration des résultats chirurgicaux, a annoncé sa participation à la Citizens Life Sciences Conference à New York. La direction de l'entreprise participera à une discussion informelle le mercredi 7 mai 2025 à 10h30 ET.
Lors de cette conférence de deux jours, prévue du 7 au 8 mai 2025, l'équipe de direction de PolyPid sera également disponible pour des rencontres individuelles avec les investisseurs. Les investisseurs intéressés peuvent organiser des rendez-vous via leurs représentants Citizens JMP.
PolyPid (Nasdaq: PYPD), ein Biopharmaunternehmen in der späten Entwicklungsphase, das sich auf die Verbesserung chirurgischer Ergebnisse spezialisiert hat, hat seine Teilnahme an der Citizens Life Sciences Conference in New York angekündigt. Das Management des Unternehmens wird an einem Gespräch am Mittwoch, den 7. Mai 2025, um 10:30 Uhr ET teilnehmen.
Während der zweitägigen Konferenz, die vom 7. bis 8. Mai 2025 stattfindet, steht das PolyPid-Managementteam zudem für persönliche Einzelgespräche mit Investoren zur Verfügung. Interessierte Investoren können Treffen über ihre Citizens JMP-Ansprechpartner arrangieren.
- None.
- None.
PETACH TIKVA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will participate in a fireside chat at The Citizens Life Sciences Conference taking place in New York, NY, from May 7-8, 2025.
| Citizens Life Sciences Conference Fireside Chat | |
| Date: | Wednesday, May 7, 2025 |
| Time: | 10:30 AM ET |
The PolyPid management team will participate in one-on-one investor meetings during this event. Investors interested in meeting with PolyPid around the conference should contact their Citizens JMP representative.
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
Contacts:
PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com
Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
britchie@lifesciadvisors.com
FAQ
When is PolyPid's fireside chat at the Citizens Life Sciences Conference 2025?
How can investors schedule meetings with PYPD management at the Citizens Conference?
What is the duration of the Citizens Life Sciences Conference where PYPD is presenting?
What type of company is PYPD and what is their focus?
